Study details
Enrolling now
Cannabigerol (CBG) for ADHD
University of Arkansas, Fayetteville
NCT IDNCT06115603ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
76
Study length
about 1 year
Ages
18–55
Locations
1 site in AR
About this study
This trial is testing if Cannabigerol (CBG), a treatment, helps with Attention-Deficit/Hyperactivity Disorder (ADHD). It compares CBG to a placebo over 382 days. Participants will take either CBG or a placebo and complete surveys about their symptoms.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Cannabigerol
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Global Impression of Change, Numeric Rating Scale (pain)
Body systems
Psychiatry / Mental Health